Literature DB >> 2111660

Different doses of cefetamet pivoxil (Ro 15-8075) in the treatment of acute uncomplicated gonococcal urethritis in men.

T T Tio1, I R Sindhunata, J H Wagenvoort, M F Michel, E Stolz.   

Abstract

In an open, dose-finding study, a 100% cure rate was observed in patients suffering from uncomplicated gonococcal urethritis who were treated with a single oral dose of either 1.2 g (n = 10), 0.8 g (n = 11), or 0.4 g (n = 10) of cefetamet pivoxil. The MICs of cefetamet for all gonococcal strains ranged from 0.001 to 0.12 micrograms/ml, and the MIC for 90% of the strains tested was 0.008 micrograms/ml. Cefetamet pivoxil was ineffective against Chlamydia trachomatis in 3 of 31 patients. Side effects were minor.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2111660      PMCID： PMC171667          DOI： 10.1128/AAC.34.4.674

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

Review 1.  Management of antibiotic-resistant Neisseria gonorrhoeae.

Authors:  F N Judson
Journal:  Ann Intern Med       Date:  1989-01-01       Impact factor: 25.391

2.  Comparison of HeLa 229 and McCoy cell cultures for detection of Chlamydia trachomatis in clinical specimens.

Authors:  E A Thewessen; I Freundt; J H van Rijsoort-Vos; E Stolz; M F Michel; J H Wagenvoort
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

3.  Trends in gonococcal resistance to antibiotics in Rotterdam, The Netherlands, 1975-86.

Authors:  J H Wagenvoort; J H van Rijsoort-Vos; J A Kluijtmans; M J Kieskamp; E Stolz; M F Michel
Journal:  Genitourin Med       Date:  1987-08

4.  Sensitivity to ampicillin, penicillin, and tetracyline of gonococci in Rotterdam.

Authors:  E Stolz; H G Zwart; M F Michel
Journal:  Br J Vener Dis       Date:  1974-06

5.  Comparison of oral treatment of uncomplicated urogenital and rectal gonorrhoea with cefuroxime axetil ester or clavulanic acid potentiated amoxycillin (Augmentin).

Authors:  R Schift; J van Ulsen; M C Ansink-Schipper; T van Joost; M F Michel; R K Woudstra; E Stolz
Journal:  Genitourin Med       Date:  1986-10

6.  Pharmacokinetics of cefetamet (Ro 15-8074) and cefetamet pivoxil (Ro 15-8075) after intravenous and oral doses in humans.

Authors:  J R Koup; U C Dubach; R Brandt; R Wyss; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

7.  Surveillance of the antibiotic susceptibility of non-penicillinase producing Neisseria gonorrhoeae in The Netherlands from 1983 to 1986.

Authors:  B van Klingeren; M C Ansink-Schipper; L Doornbos; A S Lampe; J H Wagenvoort; M Dessens-Kroon; M Verheuvel
Journal:  J Antimicrob Chemother       Date:  1988-06       Impact factor: 5.790

8.  Treatment of non-complicated urogenital, rectal and oropharyngeal gonorrhoea with intramuscular cefotaxime 1.0 g or cefuroxime 1.5 g.

Authors:  E Stolz; L Ong; T van Joost; M F Michel
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

9.  Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.

Authors:  C H O'Callaghan; A Morris; S M Kirby; A H Shingler
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

10.  Single dose oral norfloxacin or intramuscular spectinomycin to treat gonorrhoea (PPNG and non-PPNG infections): analysis of efficacy and patient preference.

Authors:  K Panikabutra; C T Lee; B Ho; P Bamberg
Journal:  Genitourin Med       Date:  1988-08
View more
  3 in total

Review 1.  Clinical and economic considerations in the use of third-generation oral cephalosporins.

Authors:  S T Chambers; D R Murdoch; M J Pearce
Journal:  Pharmacoeconomics       Date:  1995-05       Impact factor: 4.981

Review 2.  Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1993-04       Impact factor: 9.546

3.  MIC and disk diffusion quality control guidelines for Neisseria gonorrhoeae susceptibility tests of cefdinir, cefetamet, CI-960, fleroxacin, lomefloxacin, and temafloxacin.

Authors:  M E Erwin; R N Jones; F P Koontz; E H Gerlach; P R Murray; J A Washington
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.